Secondary preventive effects of a calcium antagonist for ischemic heart attack

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1696-1705

  Nakagomi, Akihiro ^a   Kodani, Eitaro ^a   Takano, Hitoshi ^a   Uchida, Takahiro ^b   Sato, Naoki ^a   Ibuki, Chikao ^c   Kusama, Yoshiki ^a   Seino, Yoshihiko ^c   Munakata, Kazuo ^b   Mizuno, Kyoichi ^a   Takano, Teruo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Beta blocker; Calcium channel antagonist; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; NICORANDIL; NITRATE;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMMON BILE DUCT STONE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; HUMAN CELL; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRACHEA DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VASOSPASM; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; SECONDARY PREVENTION; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 79959761409     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1078     Document Type: Article

References (36)

1. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-1428.
2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 211-247.
3. Anderson JL, Adams CD, Antman EM, Briges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction). Circulation 2007; 116: 803-877.
4. Yui Y, Shinoda E, Kodama K, Hirayama A, Nonogi H, Haze K, et al. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens 2007; 25: 2019-2026.
5. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina: A meta-analysis. Circ J 2010; 74: 1943-1950.
6. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67: 1309-1327.
7. The Japanese ß-blockers and Calcium Antagonists MyocardialInfarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovacular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969-973.
8. Karasawa A, Kubo K. Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1, 4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 1988; 47: 35-44.
9. Miwa Y, Masai H, Shimizu M. Differential effects of calcium channel blockers on vascular endothelial function in patients with coronary spastic angina. Circ J 2009; 73: 713-717.
10. Makino H, Aoki M, Hashiya N, Yamasaki K, Shimizu H, Miwa K, et al. A calcium-channel blocker, benidipine, improves forearm reactive hyperemia in patients with essential hypertension. Blood Press Suppl 2005; 1: 39-44.
11. Imai E, Horio M, Iseki K, Yamagata K, Hara S, Ura N, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 631-632.
12. Lakatos E. Sample sizes based on the log-rank statistics in complex clinical trials. Biometricks 1998; 44: 229-241.
13. Snow PJ. Effect of propranolol in myocardial infarction. Lancet 1965; 2: 551-553.
14. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. JAMA 1983; 250: 2814-2819.
15. Norwegian Multicenter Study Group. Timolol-induced reduction mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
16. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: Systemic review and meta regression analysis. BMJ 1999; 318: 1730-1737.
17. The Capricorn Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001; 357: 1385-1390.
18. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
19. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
20. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitors, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
21. Furberg CD, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality on patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
22. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
23. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: A meta-analysis. Am J Med 2009; 122: 356-365.
24. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, et al. Calcium channel blockers and cardiovascular outcomes: A meta-analysis of 175634 patients. J Hypertens 2009; 27: 1136-1151.
25. Jollis JG, Simpson RJ Jr, Chowdhury MK, Cascio WE, Crouse JR III, Massing MW, et al. Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med 1999; 159: 2341-2348.
26. Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17: 817-822.
27. Wijeysundera DN, Beattie WS, Rao V, Karski J. Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis. J Am Coll Cardiol 2003; 41: 1496-1505.
28. Kristian TN, Siesjo BK. Calcium in ischemic cell death. Stroke 1998; 29: 705-718.
29. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 33: 1442-1452.
30. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organizedprogram to initiate lifesaving treatment in hospitalized patients with heart failure). Am J Cardiol 2008; 102: 1524-1529.
31. Kohro T, Hayashi D, Yamazaki T, Nagai R; The JCAD Investigators. Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. Circ J 2010; 74: 962-969.
32. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
33. Hu FB, Stampeer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinicaldiagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134.
34. Nakatani D, Sakata Y, Mizuno H, Shimizu M, Suna S, Usami M, et al. Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era. Circ J 2009; 73: 662-666.
35. Tack CJ, Smits P, Willemsen JJ, Lenders JW, Thien T, Lutherman JA. Effect of insulin on vascular tone and sympathetic nervous system in NIDDM. Diabetes 1996; 45: 15-22.
36. Cruickshank JM. Beta-blockers and diabetes: The bad guys come good. Cardiovascular Drugs and Therapy 2003; 16: 457-470